Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
Purpose. This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients with BCR PC after primary definitive therapy and p...
Saved in:
Main Authors: | Rahul Aggarwal, Joshi J. Alumkal, Russell Z. Szmulewitz, Celestia S. Higano, Alan H. Bryce, Angela Lopez-Gitlitz, Sharon A. McCarthy, Branko Miladinovic, Kelly McQuarrie, Shibu Thomas, Ke Zhang, Eric J. Small |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Prostate Cancer |
Online Access: | http://dx.doi.org/10.1155/2022/5454727 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
by: Kristene Myklak, et al.
Published: (2011-01-01) -
Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
by: Matthew E. Johnson, et al.
Published: (2012-01-01) -
Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
by: Lior Z. Braunstein, et al.
Published: (2014-01-01) -
Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
by: Jae Heon Kim, et al.
Published: (2025-01-01) -
Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”
by: Katherine Neubecker, et al.
Published: (2017-01-01)